Ken Yamada
Stephanie Erbar
Stefano Zanotti
Shu-Bing Qian
Dr. Shu-Bing is the James Jamison Professor of Nutrition in the Division of Nutritional Sciences at Cornell University. Professor Shu-Bing Qian received PhD degree from Shanghai Jiaotong University Medical School (formerly Shanghai Second Medical University), majoring in Molecular Biology & Biochemistry. He then conducted two postdoctoral fellowships at the National Institutes of Health (Bethesda, MD) and University of North Carolina (Chapel Hill, NC).
Dr. Qian joined the Division of Nutritional Sciences at Cornell University in July 2008, was promoted to Associate Professor with tenure in 2014 and promoted to the rank of Professor in 2019. In 2009, he received the Young Investigator Award from Ellison Medical Foundation, and NIH Director's New Innovator Award. In 2010, Dr. Qian received the DOD Development Award. In 2013, Dr. Qian received the Peter Reeds Young Investigator Award. In 2014, Dr. Qian received the DOD Idea Award. In 2016, Dr. Qian was selected as an HHMI Faculty Scholar. In 2018, Dr. Qian was selected as the James Jamieson Professor at Nutrition.
Liz Clark
Liz Clark is IHRSA's first female president and chief executive officer in the association's 40-year history. She joined IHRSA at a critical time for the fitness industry and the association, and is well-equipped to double down on advocacy and communication efforts. A self-described "Energizer Bunny" and well-regarded Beltway presence, Liz is focused on making IHRSA known in Washington, D.C.
Prior to joining IHRSA in 2021, Liz spent 10 years spearheading government relations and advocacy at the National Confectioners Association (NCA), the trade association for the $44 billion candy industry. During her time, she directed the CandyPAC and was chief liaison and strategist. Among her notable accomplishments, Liz successfully lobbied to have confection manufacturing deemed "essential" during the pandemic. In 2016, she worked with congressional partners to develop the Congressional Candy Caucus and created a robust state government affairs program for the NCA.
Before her time at NCA, Liz was an executive director in the U.S. Chamber of Commerce. She was the world’s largest business federation representative on trade at the state level and worked closely with former Secretary of Education Margaret Spellings. Her focus was engaging and educating both lawmakers and the business community around trade and their role in public education, respectively. Liz previously worked at the National Paint and Coatings Association where she lobbied state and federal governments. She also directed NPCA’s chemical security committee, served as a liaison, and ran an environmental, health, and safety program.
Liz is a lifelong athlete whose commitment to fitness included rowing crew as an undergraduate at the University of Dayton. where she graduated with a B.A. in Communications. She received a Master of Arts in International Commerce and Policy from George Mason University. Liz lives in Arlington, VA, with her husband and three children.
Grace Chen
Roel Schaapveld
Roel served as Chief Operating Officer when InteRNA became operational until he was appointed Chief Executive Officer in May 2009. Prior to InteRNA, Roel was senior manager in the corporate finance biotech team at the Dutch merchant bank Kempen & Co involved in private funding, M&A and IPO’s at Euronext of life sciences companies.
Previously, he held several management positions at Kreatech Diagnostics (sold to Leica Biosystems), among which VP Corporate and Business Development.
Roel holds MSc and PhD degrees from Radboud University Nijmegen (NL). During his academic career he worked at the Roche Institute for Molecular Biology (Nutley, NJ), at the Dana-Farber Cancer Institute (Boston, MA) and at the Netherlands Cancer Institute in Amsterdam. Roel received his MBA from Nyenrode Business School (NL).
Raymond Deshaies
Lior Zangi
Lior Zangi, PhD, is an Associate Professor with Tenure at the Icahn School of Medicine at Mount Sinai, New York. He completed his education and training at the Weizmann Institute of Science, and Harvard University. He has established a new method, mRNA based, for gene delivery into skeletal and cardiac muscle. In the last two years, these mRNA delivery methods have been used for COVID19 vaccinations and promoting cardiovascular regeneration in ischemic heart disease. Currently, Prof. Zangi’s laboratory investigates mRNA delivery method into healthy or unhealthy specific cell types and organs, to fight different diseases such as heart failure and cancer.
Karin Jooss
Karin Jooss, Ph.D., is the head of research and development. She had most recently served as the executive vice president of research and chief scientific officer at Gritstone since April 2016. Prior to Gritstone, from May 2009 to April 2016, Dr. Jooss was the head of cancer immuno-therapeutics in the vaccine immuno-therapeutics department at Pfizer, Inc., a public pharmaceutical company, where she was also a member of the vaccine immuno-therapeutics leadership team and served as head of the immuno-pharmacology team with responsibilities including clinical development. Prior to joining Pfizer, Dr. Jooss served as vice president of research at Cell Genesys, Inc., from June 2005 to April 2009, and as senior director of research at Cell Genesys from July 2001 to June 2005. She is on the editorial board of Molecular Therapy and the Journal of Gene Medicine and is a member of the Immunology and Educational Committee of the American Society of Gene & Cell Therapy and the Industry Task Force of the Society for Immunotherapy of Cancer. Dr. Jooss serves on the board of directors of Fate Therapeutics, Inc. Dr. Jooss received her diploma in theoretical medicine from the University of Marburg in Germany, a Ph.D. in molecular biology from the University of Marburg in Germany and performed postgraduate work in gene therapy and immunology at the University of Pennsylvania.